Clarity Pharmaceuticals (ASX:CU6) Signs Copper-64 Supply Agreement with Nusano
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant improvements in anxiety scores.
Imricor Medical Systems (ASX:IMR) secures CE Mark approval for its Advantage-MR system under the new EU Medical Device Regulation, anticipating EU launch in June.
PainChek Ltd (ASX:PCK) secures a $1.41m R&D tax refund, advances FDA review for its Adult App, and launches the Infant App on Apple App Store.
4DMedical Limited (ASX:4DX) lodges a supplementary prospectus amending the terms of its New and Piggyback Options offers.
Pro Medicus Limited (ASX:PME) enters a multi-year AI research collaboration with UCSF to advance healthcare imaging solutions.
EBR Systems (ASX:EBR) proposes CMS approval of NTAP reimbursement for its WiSE CRT System, advancing US market strategy.
Clarity Pharmaceuticals (ASX:CU6) begins Phase II SECuRE trial with first patient treated and enhances 67Cu-SAR-bisPSMA formulation.
4DMedical Limited (ASX:4DX) converts pilot program with Integral Diagnostics into a commercial contract, expanding lung imaging technology across Australia.
Visionflex Group Limited (ASX:VFX) partners with Amplar Health to supply virtual care technology for aged care homes across Australia.